Skip to main content
Fig. 1 | Drug Safety

Fig. 1

From: Implementing Ecopharmacovigilance in Practice: Challenges and Potential Opportunities

Fig. 1

AstraZeneca’s Environmental Risk Management Plan (ERMP) concept: the ERMP is initiated during drug development to provide an early indication of any potential risks and to design an appropriate environmental testing programme for the Active Pharmaceutical Ingredient (API) in support of the Environmental Risk Assessment (ERA). After launch, the ERMP is updated as necessary if any new or emerging risks are identified as part of AstraZeneca’s internal Ecopharmacovigilance (EPV) process

Back to article page